

Announcement of executing license agreement with Nobelpharma Co., Ltd.  
(Granting the rights to development, manufacture, and sales for peptide vaccines for cancer therapy)

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) announces that OncoTherapy and Nobelpharma Co., Ltd. (the headquarter located at Chuo-ku Tokyo, Japan President : Jin Shiomura; hereinafter, “NPC”) have agreed and executed the license agreement with option rights that OncoTherapy grants NPC the exclusive rights to develop, manufacture and sell the peptide vaccines for certain cancer therapy.

(Agreement)

1. OncoTherapy grants NPC the exclusive right in Japan with option rights, to develop, manufacture and sell the specific cancer therapy peptide vaccine that OncoTherapy has the right of intellectual property for some specific cancers.  
Furthermore, OncoTherapy shall cooperate and share with NPC the necessary information on their development and manufacture.
2. NPC aims at cancer therapy for patients utilizing the OncoTherapy’s peptide vaccine.
3. OncoTherapy will receive upfront payment, milestone payment as well as royalties from NPC in accordance with the license agreement.

Nobelpharma Co., Ltd.

- Head Office : 1-17-24, Shinkawa, Chuo-ku, Tokyo
- President & CEO : Jin Shiomura
- Founding : June 6, 2003
- Line of Business : Develop, manufacture and sell pharmaceuticals and medical devices for unmet needs
- URL : <https://www.nobelpharma.co.jp/>